糖尿病药物:现在的和新兴的

Burger's Medicinal Chemistry and Drug Discovery Pub Date : 2010-09-15 DOI:10.1002/0471266949.BMC198

J. Tilley, J. Grimsby, S. Erickson, Berthel Steven Joseph

{"title":"糖尿病药物:现在的和新兴的","authors":"J. Tilley, J. Grimsby, S. Erickson, Berthel Steven Joseph","doi":"10.1002/0471266949.BMC198","DOIUrl":null,"url":null,"abstract":"This chapter includes a summary of the mechanism of action, history, and ADME properties compounds selected from four classes of marketed drugs for the treatment of type 2 diabetes. These include the biguanides (metformin), α-glucosylase inhibitors, sulfonylureas, and glinides. In addition, a discussion of several advanced, emerging classes of drugs together with lead structures is provided. The mechanistic classes of emerging drugs include inhibitors of the sodium glucose cotransporter 2 (SGLT2), glucokinase activators (GKAs), inhibitors of fructose-1,6-bisphosphatase (FPase), inhibitors of 11-β-sterol dehydrogenase (11-β-HSD1), agonists acting on the G-coupled-protein receptor GPR119, and mimics of the sirtuin family member SIRT1. \n \n \nKeywords: \n \ndiabetes; \nglucokinase; \nmetformin; \nsodium glucose cotransporter; \nsalfonyl urea","PeriodicalId":9514,"journal":{"name":"Burger's Medicinal Chemistry and Drug Discovery","volume":"16 1","pages":"1-38"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Diabetes Drugs: Present and Emerging\",\"authors\":\"J. Tilley, J. Grimsby, S. Erickson, Berthel Steven Joseph\",\"doi\":\"10.1002/0471266949.BMC198\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This chapter includes a summary of the mechanism of action, history, and ADME properties compounds selected from four classes of marketed drugs for the treatment of type 2 diabetes. These include the biguanides (metformin), α-glucosylase inhibitors, sulfonylureas, and glinides. In addition, a discussion of several advanced, emerging classes of drugs together with lead structures is provided. The mechanistic classes of emerging drugs include inhibitors of the sodium glucose cotransporter 2 (SGLT2), glucokinase activators (GKAs), inhibitors of fructose-1,6-bisphosphatase (FPase), inhibitors of 11-β-sterol dehydrogenase (11-β-HSD1), agonists acting on the G-coupled-protein receptor GPR119, and mimics of the sirtuin family member SIRT1. \\n \\n \\nKeywords: \\n \\ndiabetes; \\nglucokinase; \\nmetformin; \\nsodium glucose cotransporter; \\nsalfonyl urea\",\"PeriodicalId\":9514,\"journal\":{\"name\":\"Burger's Medicinal Chemistry and Drug Discovery\",\"volume\":\"16 1\",\"pages\":\"1-38\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Burger's Medicinal Chemistry and Drug Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/0471266949.BMC198\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Burger's Medicinal Chemistry and Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/0471266949.BMC198","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

摘要

本章概述了从四类已上市的治疗2型糖尿病的药物中选择的化合物的作用机制、历史和ADME特性。这些药物包括双胍类药物(二甲双胍)、α-葡萄糖酶抑制剂、磺脲类药物和格列尼德。此外，还讨论了几种先进的、新兴的药物以及铅结构。新出现的机制类药物包括葡萄糖钠共转运蛋白2 (SGLT2)抑制剂、葡萄糖激酶激活剂(GKAs)、果糖-1,6-双磷酸酶(FPase)抑制剂、11-β-甾醇脱氢酶(11-β-HSD1)抑制剂、作用于g偶联蛋白受体GPR119的激动剂，以及sirtuin家族成员SIRT1的模拟物。关键词:糖尿病;葡糖激酶;二甲双胍;葡萄糖共转运蛋白钠;salfonyl尿素

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Diabetes Drugs: Present and Emerging

This chapter includes a summary of the mechanism of action, history, and ADME properties compounds selected from four classes of marketed drugs for the treatment of type 2 diabetes. These include the biguanides (metformin), α-glucosylase inhibitors, sulfonylureas, and glinides. In addition, a discussion of several advanced, emerging classes of drugs together with lead structures is provided. The mechanistic classes of emerging drugs include inhibitors of the sodium glucose cotransporter 2 (SGLT2), glucokinase activators (GKAs), inhibitors of fructose-1,6-bisphosphatase (FPase), inhibitors of 11-β-sterol dehydrogenase (11-β-HSD1), agonists acting on the G-coupled-protein receptor GPR119, and mimics of the sirtuin family member SIRT1. Keywords: diabetes; glucokinase; metformin; sodium glucose cotransporter; salfonyl urea

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Burger's Medicinal Chemistry and Drug Discovery

自引率

0.00%

发文量